Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Anixa Biosciences Inc. Stock

Price
Target price
€3.19

€3.19

-1.690%
-0.055
-1.690%
-
 
27.07.26 / Stuttgart Stock Exchange WKN: A2N6ZF / Name: Anixa Biosciences Inc. / Stock / ? /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Anixa Biosciences Inc. in the next few years
Wizard

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Anixa Biosciences Inc. is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Anixa Biosciences Inc.

sharewise wants to provide you with the best news and tools for Anixa Biosciences Inc., so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 with Selection of Cytovance Biologics for cGMP Manufacturing
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 with Selection of Cytovance Biologics for cGMP Manufacturing

Follows positive Phase 1 results with 74% of participants demonstrating protocol-defined immune responses

 

SAN JOSE, Calif., April 1, 2026 -- Anixa Biosciences, Inc. (“Anixa” or the

irwpresse_en 
0 01.04.26
Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

Notice of Allowance marks first Korean patent covering Anixa’s breast cancer vaccine platform

 

Expands global intellectual property coverage in markets with increasing breast cancer

irwpresse_en 
0 09.03.26
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress

Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine Data

 

SAN JOSE, Calif., March 2, 2026 – Anixa

irwpresse_en 
0 02.03.26
Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

Multiple patients substantially exceed expected survival at low dose levels; absence of dose-limiting toxicities supports escalation to doses up to 100x higher

 

Trial expansion reflects

irwpresse_en 
0 09.02.26
Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future CommercializationPhoto, wide shot, wide-angle lens, Medical device manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/3a7f6312-1eee-4702-9005-93cc1e62f970.png
Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

SAN JOSE, Calif., February 2, 2026 – Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today

irwpresse_en 
0 02.02.26